Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging‐Alzheimer's Association diagnostic guidelines for Alzheimer's disease
The DOI matches its Crossref record.
Abstract
The publication of revised criteria/guidelines for the diagnosis of Alzheimer's disease (Dx-AD) in the current issue of Alzheimer's & Dementia is a momentous milestone in the prolonged history of efforts to characterize the distinct clinical-pathological features of a complex syndrome—Alzheimer's disease (AD). The amendments to the current criteria recommended by the National Institute on Aging (NIA)-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease represent significant progress in that endeavor by adding important new features that would enhance the precision and accuracy of differential diagnosis of this syndrome. These revisions promise to have a profound impact on the pace and direction of future research as well as the global effort to find a cure. Our field owes a great debt of gratitude to the members of the three workgroups, as well as to the NIA and the Alzheimer's Association, for their leadership in crafting the first significant revision of the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria [1] of 1984. Much of what the NIA-Alzheimer's Association workgroups are recommending is a redefinition of AD to include 3 stages: 1) a dementia stage for which the original NINCDS/ADRDA and the revised National Institute on Aging/Alzheimer's Association criteria apply; 2) a mild cognitive impairment (MCI) stage where there are core criteria for MCI but only guidelines of how to relate MCI to AD after further research and validation of biomarkers; and 3) a preclinical stage where there are no criteria for diagnosis but, instead, presentation of a staging hypothesis for further research related to the use of biomarkers to identify people with changes in the brain consistent with those seen later in MCI and AD dementia. An important point for all three stages is that the workgroups have created a framework for research on the relationship of the underlying pathophysiology to the emergence of clinical symptoms. In addition, for MCI and AD dementia, basic diagnostic criteria for use in current clinical practice are presented. The purpose of this editorial is to provide a brief historic context to the significance of the proposed revisions to the Dx-AD criteria and offer recommendations for further action in the future concerning this "work-in-progress." One of the questions concerning this revision is—why there was a 27 years hiatus between the publication of the original criteria and current version? Perhaps the next reiterations of these criteria will occur at regular and shorter intervals. The issue of a long lag time between re-evaluation/revision of Dx-AD criteria is a serious matter for future progress in the field; however, this concern needs to be moderated in the context of early struggles to advance the field. Although the study of dementia has a 100-year history, systematic efforts to address the array of scientific and clinical challenges to differential diagnosis of AD syndrome is a relatively recent phenomenon. Thus, several hurdles had to be overcome before the 1984 NINCDS-ADRDA criteria as well as during the intervening period between 1984 and 2011 (e.g., the lack of validated assessment tools, the necessary infrastructure for systematic clinical/longitudinal studies). Historically, one of the early core issues for the field of dementia was the question of whether AD changes are simply an accentuation of normal senescence. Even today, this problem remains to be a critical challenge. The landmark investigations by Blessed et al [2] began to address this issue in late 1960s and set the stage for the subsequent efforts to distinguish brain changes owing to pathology from those associated with healthy aging. In the United States, the trend for integrating clinical and biological studies of dementia (i.e., clinico-pathological correlations) started to take shape a decade later in parallel with advances in neurochemistry, histology, electron microscopy, neuroanatomy, molecular biology, genetics, and imaging. The critical event that set the stage for this approach was the 1977 seminal workshop (published in 1978) organized by the NINCDS, NIA, and National Institute of Mental Health, chaired by Robert Katzman, Robert Terry, and Katherine Bick [3]. Subsequently, in 1978, the NIA began to build its extramural program on AD by focusing on developing the infrastructure and tools for such clinical-pathological studies. The institute placed high priority on developing, standardizing, and validating various assessment instruments, diagnostic procedures, as well as fostering the formulation of distinct diagnostic criteria for clinical workup and neuropathological evaluation [[4]–[6]]. These early efforts by NIA led to the creation of an array of quantitative measures of cognition. Other program initiatives, which promoted the validation of instruments for objective ev
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., & Walhovd, K. B. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.004 · Cited by 799
“…causes of neural system vulnerability rather than solely on AD-specific degeneration (Jagust, 2013), and Khachaturian proposed that we should focus less on single etiological factors and rather study the full spectrum of pathogenesis in favor of a system-level approach (Khachaturian, 2011).”
BackgroundMild cognitive impairment: pathology and mechanisms
Mufson, E. J., Binder, L., Counts, S. E., DeKosky, S. T., deToledo-Morrell, L., Ginsberg, S. D., Ikonomovic, M. D., Perez, S. E., & Scheff, S. W. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0884-1 · Cited by 257
Imaging markers for Alzheimer disease: Which vs how
Frisoni, G. B., Bocchetta, M., Chételat, G., Rabinovici, G. D., de Leon, M. J., Kaye, J., Reiman, E. M., Scheltens, P., Barkhof, F., Black, S. E., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31829d86e8 · Cited by 225
“Visual read 79 (75–83) 616 (10) 75 (67–82) 245 (6) 70 (65–74) 526 (12) 60 (51–68) 171 (7) e1, e30, e53, e87, e90, e91, e99–e108”
InfluentialMorris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Gámez-Valero, A., Campdelacreu, J., Vilas, D., Ispierto, L., Reñé, R., Álvarez, R., Armengol, M. P., Borràs, F. E., & Beyer, K. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0169-5 · Cited by 167
(2012) · doi:10.1038/nrneurol.2012.118 · Cited by 122
Gossye, H., Van Broeckhoven, C., & Engelborghs, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00757 · Cited by 34
Metadata
- Authors
- Khachaturian, Z. S.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-05
- Volume
- 7
- Issue
- 3
- Pages
- 253-256
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2053449930
- Cited by
- 68
- References
- 0
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.